Volanesorsen, targeting apolipoprotein C-III, shows efficacy in reducing TG levels by over 70% in patients with familial chylomicronemia syndrome and hypertriglyceridemia during phase III trials, but it comes with a risk of thrombocytopenia.266. Here, APOC3 is linked to hypertriglyceridemia.